Gershenson DM, Miller A, Brady WE, Paul J, et al. Trametinib versus standard of care in patients with recurrent low-grade serous
ovarian cancer (GOG 281/LOGS): an international, randomised, open-label,
multicentre, phase 2/3 trial. Lancet 2022;399:541-553.
PMID: 35123694